FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation-π interactions by Qamar, Seema et al.
Article
FUS Phase Separation Is Modulated by a Molecular
Chaperone and Methylation of Arginine Cation-p
InteractionsGraphical AbstractHighlightsd Intermolecular b sheet hydrogen bonding and cation-p
interactions drive FUS demixing
d Cation-p interactions form between C-terminal arginines
and N-terminal tyrosines
d Cation-p strength is regulated by arginine methylation and
interacting proteins
d FUS hypomethylation in FTLD induces FUS gelation and
impairs RNP granule functionQamar et al., 2018, Cell 173, 720–734
April 19, 2018 ª 2018 The Authors. Published by Elsevier Inc.
https://doi.org/10.1016/j.cell.2018.03.056Authors
Seema Qamar, GuoZhen Wang,
Suzanne J. Randle, ..., Tuomas Knowles,
Michele Vendruscolo,
Peter St George-Hyslop
Correspondence
p.hyslop@utoronto.ca
In Brief
Phase transition of the RNA-binding
protein FUS is mediated by cation-p
interactions between C-terminal
arginines and N-terminal tyrosines and is
modulated by arginine methlylation.
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Reversible phase separation underpins the role of
FUS in ribonucleoprotein granules and other mem-
brane-free organelles and is, in part, driven by the
intrinsically disordered low-complexity (LC) domain
of FUS. Here, we report that cooperative cation-p
interactions between tyrosines in the LC domain
and arginines in structured C-terminal domains also
contribute to phase separation. These interactions
are modulated by post-translational arginine methyl-
ation, wherein arginine hypomethylation strongly
promotes phase separation and gelation. Indeed,
significant hypomethylation, which occurs in FUS-
associated frontotemporal lobar degeneration
(FTLD), induces FUS condensation into stable inter-
molecular b-sheet-rich hydrogels that disrupt RNP
granule function and impair new protein synthesis
in neuron terminals. We show that transportin acts
as a physiological molecular chaperone of FUS in
neuron terminals, reducing phase separation and
gelation of methylated and hypomethylated FUS
and rescuing protein synthesis. These results
demonstrate how FUS condensation is physiologi-
cally regulated and howperturbations in thesemech-
anisms can lead to disease.720 Cell 173, 720–734, April 19, 2018 ª 2018 The Authors. Published
This is an open access article under the CC BY license (http://creativeINTRODUCTION
Fused in sarcoma (FUS) is an RNA-binding protein involved
in RNA transcription, splicing, transport, and translation. FUS
undergoes rapid, physiologically reversible phase separation
between dispersed, liquid droplet, and hydrogel states (Han
et al., 2012; Kato et al., 2012; Murakami et al., 2015; Patel
et al., 2015). The droplet and hydrogel states are stabilized by
hydrogen bonding between antiparallel b sheet motifs formed
by core residues 39–95 in the low-complexity (LC) domain (Mur-
ray et al., 2017) (Figure 1A). The ability of FUS and other proteins
with intrinsically disordered domains to undergo phase separa-
tion likely contributes to the role of FUS in forming transient
membrane-free organelles, such as ribonucleoprotein (RNP)
granules (Weber and Brangwynne, 2012). These dynamic struc-
tures take up, sequester, transport, and then release key RNA
and protein cargos that regulate local RNA and protein meta-
bolism in subcellular niches, such as axon terminals and den-
drites (Holt and Schuman, 2013; Sephton and Yu, 2015). When
these processes go awry (e.g., because of pathogenic missense
mutations), they trigger disease, such as familial amyotrophic
lateral sclerosis (fALS) and frontotemporal lobar degenera-
tion (FTLD).
Given the crucial role of intrinsically disordered proteins like
FUS in multiple fundamental biological processes, understand-
ing the molecular and cellular factors that control their reversible
condensation would be invaluable. This knowledge could also
yield avenues for therapeutic intervention in diseases associatedby Elsevier Inc.
commons.org/licenses/by/4.0/).
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Figure 1. Phase Separation of Full-Length FUS at Physiological Temperature and Protein Concentration Is Modulated by Salt Concentration
and Arginine Methylation
(A) Left: Schematic of domain architecture and location of tyrosine-rich and arginine-rich domains. Right: Arginine methylation species. RRM, RNA recognition
motif; RRG, arginine glycine-rich domain.
(B) Salt-dependent phase separation of ADMA FUS and HYPO FUS. Top: Representative images of phase separation of 1 mM EmGFP-tagged ADMA FUS
in 50–150 mM NaCl. At 150 mM NaCl, ADMA FUS is mono-dispersed, but phase separates into spherical droplets at lower salt concentrations. Middle:
Representative images of ADMA FUS for KCl concentrations of 50–150 mM. Bottom: Identically prepared HYPO FUS phase separates at higher salt concen-
trations (100 mM) into small, irregularly shaped condensates. White boxes indicate location of magnified images in (C). Scale bar, 25 mm.
(C) High-magnification images of condensates from (B). Scale bar, 5 mm.
(D) Quantitative analysis of sphericity: ADMA FUS condensates (gray) in 50 mM NaCl are spherical. HYPO FUS condensates (red) are less spherical (t = 3.47,
p = 0.0006). nR 121 particles/FUS subtype; n > 3 independent replications. Error bars, SEM.
(E) Sequential structured illuminationmicroscopy images of individual droplet collisions at 0, 200, and 680ms. ADMA FUS (top) fuse. HYPOFUS collide but do not
fuse. Scale bar, 2 mm. See Video S1 (ADMA FUS) and Video S2 (HYPO FUS).
(F) Representative images and quantitative turbidity graphs of phase separation arising from mixing EmGFP-tagged ADMA FUS with the indicated percentage
of fully unmethylated UM FUS. Preparations containing > 1% UM FUS form small non-spherical, non-fusing, and amorphous assemblies. Scale bar, 25 mm.
Two-way ANOVA with Bonferroni post hoc test versus ADMA FUS at 40 mM, nR 3 replications, **p < 0.01, ***p < 0.001. Error bars, SEM.
See also Figure S1 and Videos S1 and S2.with aberrant assembly of these proteins, such as FUS-associ-
ated ALS (fALS-FUS) and frontotemporal lobar degeneration
(FTLD-FUS).
A potentially powerful clue to the identity of such factors is
the observation that arginines in FUS, which are predominantlylocated in the structured C-terminal domain (sCTD), are normally
heavily methylated as mono- or dimethylated forms (Figure 1A)
(Rappsilber et al., 2003). However, in FTLD-FUS, FUS is
hypomethylated and accumulates in neurons as nuclear and
cytoplasmic aggregates that frequently also contain EWS,Cell 173, 720–734, April 19, 2018 721
TAF15, and transportin 1 (TNPO1) (Dormann et al., 2012; Neu-
mann et al., 2012). These observations suggest that physiolog-
ical fluctuations in its arginine methylation and/or its interactome
might physiologically control FUS phase behavior.
To assess this possibility, we investigated the effect of manip-
ulating (1) the number and post-translational methylation state of
arginines (Figure 1A) and (2) the interactions with known FUS-
binding proteins. These experiments confirm that FUS phase
separation is exquisitely modulated by (1) arginine methylation
state (which tunes the strength of cation-p interactions between
the structured C-terminal and the disordered N-terminal do-
mains) and (2) binding of TNPO1, which acts as a molecular
chaperone in peripheral compartments of neurons. Crucially,
hypomethylation of FUS promotes formation of stable conden-
sates comprising intermolecular b-sheet-rich FUS assemblies
that disrupt RNP granule function in neuronal terminals and
cause FTLD-FUS.
RESULTS
FUS Phase Behavior In Vitro Is Modulated by Salt and
FUS Concentration
Prior work has established that the LC domain of FUS can form
b-sheet-rich condensates when cooled at high protein concen-
trations (50–133 mM) in the presence of crowding agents (e.g.,
polyethylene glycol and dextran). However, to gain a quantitative
understanding of how regions outside the LC domainmight influ-
ence the phase behavior of full-length FUS, we expressed and
purified wild-type, full-length human FUS from eukaryotic Sf9
cells with or without an Emerald GFP (EmGFP) tag. We chose
this system over bacterial production systems because it allows
analysis of FUS that has undergone physiological eukaryotic
post-translational modification. We then used this material to
explore the impact of variations in temperature (4C–37C) and
salt (50–150 mM NaCl or KCl) at physiological FUS protein con-
centrations (%5 mM).
These experiments revealed that variations in temperature
(4C–37C) had little effect on the phase state of full-length
FUS at physiological concentrations (1 mM). In contrast, FUS
phase behavior was profoundly affected by variations in the con-
centration of salts, such as NaCl and KCl. Specifically, at 1 mM
FUS, decreasing concentrations of NaCl or KCl from 150 to
50 mM caused rapid phase separation of FUS into hundreds of
small droplets (2.29 ± 0.15 mm diameter; n = 128 assemblies)
(Figure 1B). These assemblies, which appeared within seconds,
were approximately spherical (Figures 1C–1E), and underwent
fusion events that could be monitored using structured illumina-
tion microscopy (Figure 1E; Video S1). These effects were not
influenced by the presence or the absence of an EmGFP tag.
Hypomethylation of Selected FUS Arginines Promotes
Phase Separation
To explore the effects of changes in FUS methylation, we iso-
lated full-length, wild-type human FUS, with or without an
EmGFP tag, from eukaryotic Sf9 cells grown in the presence of
25 mM adenosine-2,3-dialdehyde (AdOx), a widely used inhibitor
of arginine methyltransferase activity (Dormann et al., 2012).
Arginine methyltransferases are components of RNP granules722 Cell 173, 720–734, April 19, 2018and therefore likely relevant to the biology of FUS phase separa-
tion (Scaramuzzino et al., 2013). Western blots of FUS protein
from AdOx-treated cells showed a significant reduction in asym-
metrically dimethylated FUS (ADMA FUS) (Figures 1A and S1A).
To identify which arginines were methylated and to quantita-
tively assess the reduction in arginine methylation induced
by AdOx, we used both isobaric tags for relative and absolute
quantitation (iTRAQ) and spectral counting mass spectrometry
methods. In full-length FUS from untreated Sf9 cells, methylation
was not homogeneously distributed across all 37 arginines (Fig-
ure S1B). At least 9 arginines were dimethylated, and these were
predominantly located in glycine-rich clusters. However, several
arginines were predominantly unmethylated, even when neigh-
boring arginines were dimethylated. The effect of AdOx was
also nonuniform. Thus, arginines 216, 259, 407, 473, and 476
were converted from a significantly dimethylated state to a pre-
dominantly mono- or unmethylated state. In contrast, arginines
394 and 481 remained predominantly dimethylated (Figure S1B).
These differences were robust, being replicated in both the
iTRAQ and the spectral counting analyses and were not altered
by the presence or the absence of the EmGFP tag.
To assess the effects of reduced methylation on FUS phase
behavior, we repeated the phase transition experiments on
hypomethylated FUS (HYPO FUS) purified from AdOx-treated
Sf9 cells. HYPO FUS condensed into many small assemblies
(1.46 ± 0.11 mm), often with non-spherical shapes, fewer fusion
events, and right-shifted the phase diagram in a manner similar
to the effects of fALS- FUS mutations (Figures 1B, 1D, 1E, and
2B; Video S2; ADMA FUS, black; FUS P525L, green; HYPO
FUS, lower red line; p < 0.0006). These differenceswere not influ-
enced by the EmGFP tag.
The dramatic effect of FUS arginine methylation on phase sep-
aration raises the question of what proportion of FUS needs to
be hypomethylated before significant changes in phase behavior
could occur. If this proportion was small, then modulating FUS
methylation might provide a physiological mechanism to dynami-
cally change FUS assembly. Furthermore, if this process became
uncontrolled, theaccumulationofexcessivequantitiesofhypome-
thylatedFUSmight thencausediseasebypromoting the formation
of stable and biologically irreversible fibrillar hydrogel assemblies
in a manner analogous to fALS-FUS mutations (Murakami et al.,
2015). Toaddress thisquestion,we repeated thephaseseparation
experiments at the boundary conditions of 2 mM full-length FUS
and 40 mM NaCl at 23C, but included varying quantities of fully
unmethylated FUS (UM FUS) purified fromE. coli (0.5%–5%of to-
tal FUS). These studies revealed that when UM FUS comprised
more than 1% of total FUS there was (1) increased formation of
small non-spherical, non-fusing assemblies and (2) the appear-
ance of larger diffuse assemblies that are likely fibrillary hydrogel
condensates (Figure 1F,middle and lower panels, p < 0.01). These
results indicate that even small quantities of unmethylated FUS
(<5%)could induce transitionofdispersedFUS into liquiddroplets
and its gelation into irreversible fibrillar condensates.
Cation-p Interactions Participate in FUS Phase
Separation
Our observation that differential methylation of arginines in
the C-terminal structured domain of FUS can modulate phase
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separation in a salt-dependent manner raises the question of
what these arginines interact with during condensation. FUS
contains only 5 acidic residues in the LC domain, making these
unlikely to be the principal drivers of the implied electrostatic
interaction. However, FUS has 27 tyrosines (but no tryptophan
or phenylalanine) in the LC domain, which might allow protons
in the guanidino moiety on the arginine side-chains to form
cation-p interactions with electrons in the benzene ring of
tyrosines.
To explore this idea, we investigated phase separation in pu-
rified full-length FUS proteins in which (1) multiple arginines in
the sCTD were mutated to alanine or lysine or (2) multiple tyro-
sines in the LC domain weremutated to alanine or phenylalanine.
In the arginine mutagenesis studies, we focused on the six argi-
nines (216, 259, 407, 472, 473, and 476) that showed the greatest
variability in methylation state after AdOx treatment. In the tyro-
sine mutagenesis studies, we focused on seven ‘‘near core’’
tyrosines (hereafter ‘‘ncYs’’: 113, 122, 130, 136, 143, 149, and
161) adjacent to the b-sheet-forming core of the LC domain
(amino acids [aa] 39–95). We chose not to investigate tyrosine
replacement in the core LC domain to avoid confounding the
experiment by disrupting the ability of the core domain to form
anti-parallel b sheet assemblies.
FUS phase separation was abrogated when cation-p interac-
tions were disrupted by (1) replacement of arginines with alanine
(FUS 6R/A) (Figure 2A), (2) enzymatic conversion of arginine to
citrulline (Cit-FUS) by protein arginine deiminase (PAD), which
replaces the positively charged ketimine group ( = NH) with an
uncharged ketone group ( = O) (Figures 2A, 2E, and S2), and
(3) conversion of the ncYs to alanine (FUS ncY/A) (Figures 2A
and 2D). However, phase separation was maintained when
cation-p interactions were preserved by (1) substitution of the ar-
ginines with lysine (FUS 6R/K), which has a cationic side chain,Figure 2. Phase Separation Is Driven by Cation-p Interactions betwee
Tyrosines near the Core of the LC Domain (ncY)
For a Figure360 author presentation of Figure 2, see the figure legend at https://
(A) The strength of cation-p interactions can be modulated by varying the numb
Representative images of phase separation by EmGFP-tagged ADMA FUS in 50
alanine (6R/A) abrogates phase separation. Row 3: Enzymatic conversion of a
arginines to lysine (6R/K) preserves phase separation. Row 5: Mutating ncYs 11
Row 6: Mutating the same tyrosines to phenylalanine (ncY/F) preserves pha
FUS +16R, FUS +21R) permits phase separation at higher salt concentrations
separation (150 mM). Scale bar, 25 mm.
(B) Phase separation/turbidity diagram for constructs in (A). Error bars, SEM; nR
(C) Representative images of highly spherical ADMA FUS and FUS 6R/K
FUS +16R ncY/A mutations.
(D) Circularity (sphericity) graph: ADMA FUS are spherical. Replacing ncYs with
gression to gelation (Student’s t test, Satterthwaite method for unequal variances:
phenylalanine (ncY/F) supports normal phase separation (t = 1.69, df = 213, p
circularity (i.e., FUS +9R, FUS +16R, FUS +21R) (Student-Newman-Keuls multiple
augmented cation-p drive in FUS +16R by reducing the available near-core tyr
(FUS +16R-ncY/A vs. FUS+16R: t = 16.84, df = 987, p = 3.97 3 1056); FUS
independent replications. Error bars, SEM.
(E) Schematics of PRMT-mediated dimethylation of arginine to create ADMA FUS
between tyrosine rings and arginine guanidino side chain.
(F) Tyrosine-rich LC domain and arginine-rich sCTD cooperatively support phase
alone (left) and mCherry-CTD (aa 215–526) alone (right) at 1 mM FUS, 50 mM
separation occurs upon mixing LC domain (green) with sCTD (red). Merged (oran
See also Figure S2.
724 Cell 173, 720–734, April 19, 2018or (2) substitution of ncYs by phenylalanine (FUS ncY/F), which
contains an aromatic ring in its side-chain (Figures 2A, 2C,
and 2D).
Next, we investigated the effect of increasing the cation-p
drive by strategic substitution of 9, 16 or 21 additional arginines
to create more RGG and GRG motifs in the sCTD (FUS +9R,
FUS +16R, and FUS +21R, respectively). The circular dichroism
(CD) spectra of these proteins were indistinguishable from either
ADMA FUS or HYPO FUS, implying that they were properly
folded (Figure S2A). However, these constructs had significantly
increased propensity to phase separate (as measured by
turbidity; Figure 2B) and form gel-like structures (as measured
by increasing numbers of nonspherical condensates; Figures
2C and 2D). This behavior was strongly dependent on the num-
ber of extra arginines (Figures 2A and 2B). To confirm that this
effect was due to enhanced cation-p interactions, we mutated
the ncYs to alanine in the construct with 16 extra arginines
(FUS +16R ncY/A), thereby reducing the number of tyrosines
available to form cation-p interactions with the extra arginines
in the parental FUS +16R construct. This FUS +16R ncY/A
construct rescued liquid droplet formation (Figures 2A, 2C,
and 2D).
To examine the implied cooperativity between the tyrosine-
rich disordered LC domain and the arginine-rich sCTD we sepa-
rately purified these two domains and investigated their phase
behavior alone or mixed together. The EmGFP-tagged LC frag-
ment formed droplets and gels when cooled at high concentra-
tions (>50 mM FUS), but did not phase separate at 1 mM at
23C, even when mixed with dextran (Figure 2F). The mCherry-
tagged arginine-rich sCTD also showed minimal phase separa-
tion under these conditions (Figure 2F). In contrast, robust phase
separation rapidly occurred when the LC and sCTD fragments
were mixed at 1:1 molar ratios, even in the absence of crowdingn Arginines in RGG Motifs in the Structured C-Terminal Domain and
doi.org/10.1016/j.cell.2018.03.056.
er of arginine residues or by varying the number of tyrosine residues. Row 1:
150 mM NaCl. Row 2: Mutating arginines 216, 259, 407, 472, 473, and 476 to
rginines to citrullines abrogates phase separation. Row 4: Mutation of these
3, 122, 130, 136, 143, 149, 161 to alanine (ncY/A) reduces phase separation.
se separation. Rows 7, 8, and 10: Addition of arginine residues (FUS +9R,
. Row 9: Adding ncY/A to FUS +16R (FUS +16R ncY/A) rescues phase
3 replications.
assemblies. The nonspherical FUS +16R droplets can be rescued by
alanine (ncY/A) increases circularity, likely because there is reduced pro-
t = 7.46, degrees of freedom [df] = 155, p = 5.913 1012). Replacing ncYs with
= 0.092). Augmenting cation-p interactions increases gelation and reduces
comparisons of means test: F = 64.57[6, 6674], p = 2.843 10
78). Decreasing the
osines (FUS +16R ncY/A) restores normal phase separation and circularity
+16R-ncY/A versus ADAM FUS: t = 3.98, df = 257, p = 8.98x105). N > 3
; PAD-mediated conversion of arginine to citrulline; and cation-p interactions
separation. Top row: representative images of EmGFP-LC domain (aa 1–214)
NaCl, showing minimal phase separation. Bottom row: brief (<2 min) phase
ge). Scale bar, 25 mm.
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Figure 3. FUS Phase Separation in SH-SY5Y Cells Is Modulated by FUSMethylation, by the Number of Tyrosines near the LC Core (ncY), and
Number of Arginines in the sCTD
For a Figure360 author presentation of Figure 3, see the figure legend at https://doi.org/10.1016/j.cell.2018.03.056.
(A) Representative images of FUS granules in SH-SY5Y cells expressing either YFP-tagged FUS, with or without AdOx treatment (HYPO or ADMA FUS
respectively), or FUS with variations in the number of tyrosines or arginine. More cells had granules after AdOx treatment (HYPO FUS) and after expressing FUS
with additional arginines (e.g., FUS +9R etc). Fewer cells had FUS granules after expressing FUS with tyrosines converted to alanine (ncY/A). Cells with
tyrosines converted to phenylalanine (ncY/F) had normal granule formation. Scale bar, 10 mm.
(B) AdOx causes a dose-dependent increase in cells with FUS granules. n = 100–200 cells/replicate experiment. Mean ± SEM, n = 5 replicates **p < 0.01,
***p < 0.001, one-way ANOVA with Dunnett’s post hoc test.
(C) Quantification of the number of cells in (A) with clusters of condensed FUS granules, comparing cells expressing wild-type FUS versus cells expressing
FUS in which tyrosine residues in the N-terminal LC domain are mutated to alanine (inhibits cation-p interactions) or mutated to phenylalanine (maintains
cation-p interactions). n > 200 cells/replicate. One-way ANOVA with Dunnett post hoc test, n = 3–7 independent replications, *p < 0.05, ***p < 0.001. Error
bars, SEM.
(legend continued on next page)
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agents (Figure 2F). However, unlike condensates from full-length
FUS, these condensates were unstable, and dissolved within
minutes, implying that full stabilization of condensed polymers
requires tethering of the LC domain to the sCTD.
Arginine:Tyrosine Cation-p Interactions Modulate FUS
Phase Separation in Cells
Next, we investigated FUS phase separation in SH-SY5Y cells
transiently expressing either YFP-tagged full-length FUS or
YFP-tagged versions of the arginine or the tyrosine-modified
FUS constructs described above. These cells were then treated
for 24 hr with either DMSO control or varying doses (0–20 mM)
of AdOx. Hypomethylation of FUS was confirmed by western
blotting (Figure S3A).
The results of these cellular studies were in good agreement
with our initial biochemical studies. Thus, SH-SY5Y cells ex-
pressing FUS ncY/F, which have intact cation-p drive, were
indistinguishable from cells expressing ADMA FUS (Figure 3C).
Similarly, AdOx treatment and expression of FUS constructs
with additional arginines caused a significant increase in the
number of cells displaying intracellular FUS granules (Figures
3A and 3B; p < 0.01). The visible FUS aggregates were accom-
panied by increased abundance of FUS in RIPA-insoluble frac-
tions of cell lysates (Figures 3A, 3D, 3E, and S3B). Crucially,
the magnitude of these increases were dependent on the
AdOx dose or number of extra arginines respectively. By
contrast, FUS granule formation was significantly reduced in
cells expressing FUS variants that diminish cation-p drive (either
FUS ncY/A or FUS 6R/A) (Figures 3C and S3B–S3D).
These experiments support the notion that differential methyl-
ation of arginines in the sCTD of FUS can regulate FUS assembly
through modification of cation-p interactions with tyrosines in
the N-terminal LC domain.
TNPO1, but Not EWS or TAF15, Acts as a Molecular
Chaperone for FUS
Because hypomethylated FUS deposits in FTLD-FUS brain tis-
sue contain EWS, TAF15 and TNPO1, we wondered whether
these proteins might modulate FUS phase behavior. We there-
fore performed protein mixing experiments in which purified
ADMA FUS or HYPO FUSweremixed with equimolar concentra-
tions of TNPO1, EWS, TAF15, BSA, or buffer alone, and the
phase separation behavior was investigated as above. When
ADMA FUS or HYPO FUS were mixed with TAF15, EWS, or
BSA, their phase behavior was essentially indistinguishable
from ADMA FUS or HYPO FUS alone (Figures 4A and 4B). How-
ever, TNPO1 strongly suppressed phase separation of both
ADMA FUS and HYPO FUS (Figures 4A, fourth column, and
4B, p < 0.001, n = 6 replications).
Similar results were obtained in cell-based experiments in
SH-SY5Y cells expressing YFP-FUS together with mCherry vec-(D) Quantification of the number of cells in (A) with clusters of condensed FUS gra
with increasing numbers of additional arginine residues in the structured C-termin
n = 3–7 independent replications, *p < 0.05, ***p < 0.001. Error bars, SEM
(E) Quantification of RIPA-insoluble FUS, normalized to input, in cells expressi
One-way ANOVA with Dunnett’s post hoc test, n = 4, *p < 0.05, ***p < 0.001. Err
See also Figure S3.
726 Cell 173, 720–734, April 19, 2018tor alone, mCherry-EWS, mCherry-TAF15, or mCherry-TNPO1.
Thus, although both EWS and TAF15 colocalized with HYPO
FUS granules induced by AdOx, their co-expression had no
impact on granule formation (Figure 4C, top-right and bottom-
left panels; Figure 4D, p < 0.001, n = 8 replications). By contrast,
TNPO1, suppressed FUS granule formation, and TNPO1 was
largely absent fromHYPOFUS granules that did form (Figure 4C,
lower-right panel; Figure 4D; p < 0.001, Figure 4E, p < 0.05, n = 8
replications). These inhibitory effects of TNPO1were not attribut-
able to (1) TNPO1-induced changes in the abundance or methyl-
ation state of FUS (Figure S4A) or (2) AdOx-induced changes in
the abundance of EWS, TAF15 or TNPO1 (Figure S4B).
Taken together, these experiments lead to the intriguing
conclusion that TNPO1 may act as a cellular molecular chap-
erone for both ADMA FUS and HYPO FUS.
Biophysical Analysis of FUS Phase Separation Probed
with Amyloidophylic Dyes
To gain insight into the secondary and quaternary structures of
ADMAFUS andHYPOFUS assemblies during phase separation,
we applied two complementary approaches. The first approach
employed the amyloidophylic fluorescent dyes—thioflavin T
(ThT) and pentameric formyl thiophene acetic acid (pFTAA)—
as chemical probes that could be applied to both protein and
cellular preparations. The second approach employed atomic
force microscopy-basedinfrared nanospectroscopy (AFM-IR;
see the next section).
ThT showed only minimal binding and fluorescence enhance-
ment upon addition to either purified ADMA FUSprotein conden-
sates (Figure S5A, black line) or purified HYPO FUS protein
condensates (Figure S5A, red line). By comparison, equimolar
concentrations of a-synuclein (a conventional amyloid-forming
protein) displayed robust ThT binding and fluorescence (Fig-
ure S5A, purple line). In cell-based experiments, ThT displayed
minimal binding and fluorescence to HYPO FUS in AdOx-treated
SH-SY5Y cells (data not shown). This result is in good agreement
with prior studies showing poor binding of ThT to pathological
fibrillar FUS assemblies in human FTLD-FUS and fALS-FUS
tissues and in C. elegans models (Urwin et al., 2010). Further
work with ThT was abandoned. However, pFTAA showed
more promising results.
pFTAA is a high-affinity, cell permeant, luminescent oligothio-
phene dye that discriminates different conformers of b-sheet-
containing aggregates of tau and PrP (Klingstedt et al., 2013).
pFTAA showed modest binding and fluorescence with ADMA
FUS condensates (Figure 5A, first column of images), but signif-
icantly greater binding and fluorescence with condensates
composed of HYPO FUS, FUS +9R, or FUS +16R (Figure 5A,
p < 0.001). Crucially, pFTAA was also able to detect the
chaperone-like activity of TNPO1. Thus, premixing TNPO1 with
ADMA FUS or HYPO FUS dramatically reduced the numbernules, comparing cells expressing wild-type FUS versus cells expressing FUS
al domain. n > 200 cells/replicate. One-way ANOVAwith Dunnett post hoc test,
ng ADMA FUS, HYPO FUS, FUS ncY/A, or FUS with additional arginines.
or bars, SEM.
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Figure 4. TNPO1 Is a Molecular Chaperone for ADMA FUS and
HYPO FUS
(A) Representative images of FUS phase separation in the presence of equi-
molar concentrations EWS, TAF15, or TNPO1. EWS and TAF15 had minimal
impact on FUS phase separation. TNPO1 suppressed both ADMA FUS and
HYPO FUS phase separation. Scale bar, 25 mm.
(B) Quantification of (A). Kruskal-Wallis test, Dunn’s post hoc, n = 32–35 fields
of view, *p < 0.05, ***p < 0.001. Error bars, SEM.
(C) Representative images of FUS granules in AdOx-treated SH-SY5Y cells
expressing YFP-FUS (green) and mCherry, mCherry-tagged EWS, mCherry-of assemblies that bound pFTAA (Figure S5B, p < 0.001). In cell-
based experiments, pFTAA displayed significant binding and
fluorescence with HYPO FUS condensates in AdOx-treated
SH-SY5Y cells (Figure 5B).
These experiments suggest that liquid droplet condensates
of ADMA FUS contain a small proportion of FUS in an antiparallel
b sheet conformation, and this antiparallel b sheet content is then
significantly increased upon conversion to hydrogel-like HYPO
FUS condensates.
Structural Analysis of FUS Phase Separation by AFM-IR
Nanospectroscopy
To further explore the relationship between the three-dimensional
morphology and the secondary and quaternary structures of indi-
vidual ADMA FUS and HYPO FUS assemblies, we next applied a
recently developed single-molecule technique that combines
atomic force microscopy (AFM) with infrared nanospectroscopy
(IR) (Dazzi et al., 2012). In contrast to conventional bulk ap-
proaches, AFM-IR provides a unique tool to probe, at nanoscale
resolution, the morphological, nanomechanical, chemical, and
secondary and quaternary structural properties of individual
protein assemblies, a feature crucial for characterizing heteroge-
neous molecular systems (Ruggeri et al., 2015b).
Weapplied this approach to investigateADMAFUS,HYPOFUS
andFUS+16Rcondensates generated using the same conditions
used in earlier experiments. The condensateswere placed on zinc
selenide (ZnSe)windows. AFM-IRwas then used to acquire nano-
scale resolved maps on the 3D morphological (Figure 6A) and
nanomechanical properties of the assemblies (Figure 6B). The
nanomechanical state was assessed by measuring the shifts in
the tip-sample contact resonance (Figure 6C),which variesmono-
tonically as a function of the intrinsic Young’smodulus of the sam-
ple (Dazzi et al., 2012). Because of the complexity of defining the
absolute nanomechanical properties of soft biological samples,
we measured the stiffness of each assembly relative to the stiff-
ness of the underlying ZnSewindow.We then acquired nanoscale
resolved infrared (IR) spectra from several locations within each
assembly (denotedby ‘‘+’’ in Figure 6A). Because eachnanospec-
troscopy measurement has a lateral resolution down to 20 nm
(Ruggeri et al., 2015b), it allows exquisite characterization of the
chemical properties and secondary and the quaternary chemical
structures across multiple locations in individual condensates
(Galante et al., 2016). The average spectrum from all assemblies
for each group was then calculated (Figure 6F), and the corre-
sponding average second derivatives in amide band I (Figure 6G)
were evaluated to extract the principal structural components of
the condensates. Cumulatively, we acquired 216 spectra withtagged TAF15, or mCherry-tagged TNPO1 (red). FUS granules co-localized
with EWS and TAF15, but not with TNPO1 or mCherry alone. Scale bar, 10 mm,
n = 8 replicates.
(D) Quantification of (C): FUS co-localized with EWS (100% ± 0.0%) and TAF15
(99.1% ± 1.7%). FUS poorly colocalized with TNPO1 (14.3% ± 8.5%) or
mCherry only (1.0% ± 1.4%). One-way ANOVA, Tukey’s post hoc, n = 8 rep-
licates, ***p < 0.001.
(E) TNPO1 reduced the number of SH-SY5Y cells with AdOx-induced FUS
granules. One-way ANOVA, Tukey’s post hoc, n = 8 replicates, *p < 0.05.
See also Figure S4.
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AB
Figure 5. pFTAA Differentially Binds and
Fluoresces with FUS Hydrogel Condensates
(A) Representative images of mCherry-tagged FUS
(red, top row) labeled with pFTAA (bottom row).
ADMA FUS weakly binds pFTAA. AdOx-treated
(HYPO FUS) FUS +9R and FUS +16R strongly bind
pFTAA. Kruskal-Wallis test, Dunn’s post hoc,
n > 190 droplets, n = 3 independent replications,
***p < 0.001. Error bars, SEM. Scale bar, 20 mm.
(B) AdOx-treated cells have intracellular HYPO
FUS granules that co-stain with pFTAA (bottom
row). Mann-Whitney U test, n > 140 cells over six
fields of view, ***p < 0.0001. Error bars, SEM. Scale
bar, 20 mm.
See also Figure S5.corresponding detailed nanomechanical data from ADMA FUS,
HYPO FUS, and FUS +16R assemblies.
ADMA FUS: Homogeneous Spherical Liquid-like
Structures with Low b Sheet Content
ADMA FUS condensates had relatively homogeneous morpho-
logical and mechanical properties, with high sphericity and low
relative intrinsic stiffness akin to that of a liquid. In agreement
with the nanomechanical data, the chemical responses of
different ADMA FUS liquid droplets were also relatively homoge-
neous, all being composed of a-helical, native b sheet, random
coil, b-turn, and residual antiparallel intermolecular/cross-b
sheet structures (Figures 6D, top panel, and S6A–S6D).
HYPO FUS: Heterogeneous Assemblies with Liquid- and
Gel-like Condensates
By contrast, HYPO FUS condensates were bothmorphologically
and mechanically heterogeneous. Crucially, this heterogeneity
existed both within individual HYPO FUS assemblies and be-
tween different HYPOFUS condensates (Figures 6A–6D, second
row, and S6A). This intra-sample heterogeneity is quantitatively
demonstrated in Figure 6 for a representative HYPO FUS
condensate. This particle has a spherical component (red circle,
middle panel, Figure 6B) fused to a non-spherical component
(orange ellipse, middle panel, Figure 6B). The spherical compo-
nent showed softer mechanical properties, like those of ADMA
FUS condensates. The nonspherical component showed stiffer
nanomechanical features more suggestive of a gel. This regional
heterogeneity within a single condensate is of note because
it suggests conversion between liquid droplet and hydrogel
conformations.
IRspectraofHYPOFUSassemblieswerealsohighly heteroge-
neous, and this heterogeneity correlated with the nanomechani-728 Cell 173, 720–734, April 19, 2018cal heterogeneity. The regions within a
single droplet possessing higher stiffness
were also the ones possessing higher
absorption at 1,695 cm1, corresponding
to antiparallel cross-b sheets. More
importantly, on average, deconvolution
of amide band I of the HYPO FUS IR
spectra revealed increased antiparallel
cross-b sheet, random coil and b-turn
content compared to ADMA FUS assem-
blies (Figures 6G, S6B, S6C, and S6E).Furthermore, amide band II of HYPO FUS assemblies was
shifted toward lower wave-numbers, confirming independently
increased hydrogen bonding (Figures 6G, S6B, S6C, and S6E).
In addition, on average, HYPO FUS assemblies had reduced
and shifted signals originating from the methyl group absorption
(das(CH3), methyl asymmetric stretching at 1,445 cm
1), confirm-
ing their lower methylation state (Figure S6F).
Remarkably, at the level of individual HYPO FUS assemblies
there was considerable heterogeneity in the spectral data.
Thus, HYPO FUS condensates with liquid-like nanomechanical
properties (e.g., within the red circle in Figure 6B) had IR spectra
like those of ADMA FUS condensates. But the HYPO
FUS condensates with stiffer nanomechanical properties (e.g.,
within the orange ellipse in Figure 6B) had higher antiparallel
cross-b sheet content and increased intermolecular hydrogen
bonding, suggesting the presence of a hydrogel-like structure
(Ruggeri et al., 2015a).
FUS +16R: Stiff, Non-spherical Parallel b-Sheet-Rich
Hydrogen-Bonded Assemblies
The FUS +16R condensates displayed a predominantly non-
spherical 3Dmorphology and stiffer nanomechanical properties,
like those of the gelled HYPO FUS condensates (Figures
6A–6D, lower panels). Quantitative analysis of the IR spectra
for FUS +16R assemblies was complicated by partial overlap
in the absorption spectra of the extra arginine side-chains, which
absorb at 1,635–1,675 cm1. As a result, it was not possible to
quantitatively compare the secondary and quaternary structural
composition of FUS +16Rwith HYPO FUS or ADMA FUS assem-
blies. Nevertheless, the spectra for FUS +16R reveal significant
intermolecular amyloidogenic antiparallel (1,695 cm1) and par-
allel b sheet (1,625 cm1) content, related to the dense network
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Figure 6. Nanoscale Resolution Analysis of the Mechanical and Secondary and Quaternary Structural Properties of Individual FUS Con-
densates Reveal Substantial Differences between ADMA FUS versus HYPO FUS and Cation-p-Enhanced FUS Condensates
For a Figure360 author presentation of Figure 6, see the figure legend at https://doi.org/10.1016/j.cell.2018.03.056.
(A) Representative AFM 3Dmorphology maps of individual ADMA FUS (top), HYPO FUS (center), and FUS +16R granules (bottom). Crosses represent position of
nanoscale localized IR spectroscopy measurements.
(B) Representative tip-sample contact resonance maps of nanoscale stiffness for ADMA FUS (top), HYPO FUS (middle), and cation-p enhanced FUS +16R
condensates (bottom). Colored circles indicate where contact resonance shift was evaluated.
(C) Histogram of tip-sample contact resonance shift (‘‘stiffness’’) for representative ADMA FUS (top), HYPO FUS (middle), and FUS +16R (bottom) condensates.
ADMA FUS and FUS +16R condensates have homogeneous (but different) nanomechanical properties. HYPO FUS condensates are heterogeneous, with softer
and stiffer regions. The colored average curves correspond to the distribution of contact resonance shifts in the colored regions in (B).
(D) Individual nanoscale raw localized spectra and their average (bold) from locations indicated by ‘‘+’’ on AFMmaps for corresponding ADMA FUS (top), HYPO
FUS (center), and FUS+16R (bottom) condensates. n = 3 independent methylated ADMA FUS assemblies; n = 4 independent hypomethylated FUS assemblies;
n = 4 for the FUS +16R assemblies. Error bars, SEM.
(E) Relative stiffness of the FUS assemblies. ADMA FUS (green) and round HYPO FUS (red) display soft nanomechanical properties. The non-spherical HYPO
FUS and FUS+16R, display stiffer properties. nR 3 independent ADMA FUS; HYPO FUS; FUS +16R condensates. Error bars, SD.
(F) Average IR spectra in amide band I and II for ADMA, HYPO, and FUS +16R, which derive from the average of the average of 55 ADMA FUS, 73 HYPO FUS, and
88 FUS +16R spectra. Error bars, SEM.
(G) Deconvolution of amide band I reveals that (1) HYPO FUS droplets (red line) have a significant increase of antiparallel b sheet, random coil and b-turn
structures, compared to the ADMA FUS droplets (green line). (2) FUS +16R assemblies (purple line) are stabilized by parallel amyloidogenic b sheet content
(1,625 cm1). Error bars, SEM.
See also Figure S6.
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Figure 7. Hypomethylation of FUS or FUS Constructs with Additional Arginines Promote FUS Granule Formation and Attenuate Axonal New
Protein Synthesis, which Is Rescued by TNPO1
For a Figure360 author presentation of Figure 7, see the figure legend at https://doi.org/10.1016/j.cell.2018.03.056.
(A) Representative images of endogenous FUS (anti-FUS antibody, green) and pFTAA binding (red and heatmaps) in fixed axon terminals, showing AdOx-induced
increased FUS aggregates and pFTAA binding (right). Scale bar, 5 mm.
(B) Quantification of the increased accumulation of endogenous FUS granules following AdOx treatment of the axon terminals in (A). The accumulation of FUS
granules was assessed by FUS immunofluorescence. Unpaired t test, n = 26 and 16 axon terminals. *p < 0.05, **p < 0.01. Error bars, SEM.
(legend continued on next page)
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of intermolecular hydrogen bonding (Ruggeri et al., 2015b),
and lead to the observed stiffer nanomechanical properties of
FUS +16R condensates.
These results support the notions that (1) both liquid droplet
and hydrogel phase transitions are associated with increasing
inter-molecular hydrogen bonding and increasing antiparallel
cross-b sheet, random coil and b-turn structures and (2) these
structural shifts are associated with selective binding of amyloi-
dophyllic dyes, such as pFTAA. Finally, the AFM-IR analyses of
FUS +16R condensates demonstrate that enhancing the argi-
nine: tyrosine cation-p interaction by increasing the number of
arginines in the C-terminal regions of FUS outside the core LC
domain, promotes formation of stabilized hydrogels. This obser-
vation suggests that FUS constructs with additional arginines
(‘‘cation-p enhanced’’ constructs) can at least partially replicate
the propensity of HYPO FUS to form pathologically stable FUS
granules, and might therefore be useful as a molecular model
of FTLD-FUS (see below).
Arginine Methylation Status Regulates Neuronal FUS
RNP Granule Function
The experiments described above support our hypothesis that
FUS phase transition can be regulated by (1) methylation of
arginines in the sCTD of FUS and (2) interactions with TNPO1.
We were therefore curious to determine whether manipulation
of the arginine methylation status of FUS and its interaction
with TNPO1 might alter FUS RNP granule function in distal
neuron terminals.
To address this question, we examined FUS assembly, FUS
conformational state, and FUS RNP granule function in
ex vivo Xenopus retinal neuron cultures prepared as previously
described (Lin and Holt, 2007). The distribution of FUS assem-
blies was assessed in mock-treated or AdOx-treated axons
(20 mM for 30 min) either by anti-FUS immunofluorescence (for
endogenous FUS) or by GFP fluorescence (for live imaging of
axonal FUS granules in neurons expressing GFP-tagged FUS)
(Figures 7A–7F). A caveat to the use of AdOx to induce hypome-
thylation of FUS is the potential for AdOx to alter the methylation
state of numerous other neuronal proteins. To circumvent
this caveat, in parallel experiments, we also expressed the
‘‘cation-p enhanced’’ constructs in axon terminals (FUS +5R,
FUS +7R, FUS +9R, FUS +16R, and FUS +21R).
In good agreement with our earlier biochemical and cellular
experiments, AdOx treatment of isolated axons and axon termi-(C) Quantification of the change in phase state of endogenous FUS granules foll
using pFTAA fluorescence intensity. Unpaired t test, n = 26 and 16 axon termina
(D) AdOx treatment (HYPO FUS) or expression of FUS with additional arginines in
axon segments, **p < 0.01, ***p < 0.001. Error bars, SEM.
(E) Number of FUS-GFP granules per 50 mm live distal axon segments following m
expressingmCherry or mCherry-TNPO1. Unpaired t test, n = 20–30 axon segmen
movement of TNPO1 (red) in FUS granules in the axon shaft of neurons express
(F) Representative images showing colocalization of FUS and TNPO1 in distal ax
(G) Representative images (pseudo-colored green) and heatmaps of puromycin-
treated (HYPO FUS, middle), or FUS +21R-GFP-expressing axon terminals (FUS
(H) Quantification of (G). Unpaired t test, n > 100 axon terminals. ns, not significa
(I) Coexpression of mCherry-TNPO1 rescues new protein synthesis in AdOx-trea
t test, n > 100 axon terminals, ns, not significant, ***p < 0.001. Error bars, SEM.
See also Video S3.nals induced the formation of bright FUS granules that showed
increased pFTAA fluorescence (Figures 7A–7F; p < 0.05,
p < 0.01), Crucially, the parallel experiments in neurons express-
ing ‘‘cation-p enhanced’’ constructs revealed an arginine dose-
dependent increase in similar axonal FUS granules (Figure 7D,
p < 0.001). pFTAA labeling was not investigated in neurons ex-
pressing ‘‘cation-p enhanced’’ constructs because the excita-
tion/emission spectra of their GFP tags overlap those of pFTAA.
Hypomethylated FUS Assemblies Impair Neuronal New
Protein Synthesis
Next, we used puromycin labeling of nascent proteins in isolated
axon terminals (Lin and Holt, 2007) to assess the impact of
AdOx (HYPO FUS) and of ‘‘cation-p enhanced’’ constructs on
FUS RNP granule function (Figures 7G–7I). These experiments
demonstrated that new protein synthesis was significantly atten-
uated in both AdOx-treated axon terminals (HYPO FUS), and in
the axon terminals expressing ‘‘cation-p enhanced’’ constructs
(Figures 7G–7I; p < 0.001). Crucially, the magnitude of this effect
(0.60–0.80 of control) approximated that of fALS-FUS muta-
tions (0.80 of control) (Murakami et al., 2015).
TNPO1 Rescues Impaired Protein Synthesis in Axon
Terminals
Outside of the nucleus, TNPO1 colocalizes with some cyto-
plasmic RNA granules, where it coexists with FUS, purine-rich
element binding protein A (Pur-a, which modulates toxicity of
ALS-associated FUS mutants), and Staufen-1 (a marker of
neuronal transport granules) (Jain et al., 2016). In this non-nu-
clear role, TNPO1 facilitates the import of protein components
into RNA granules in a Ras-related nuclear protein-GTP-inde-
pendent fashion (Twyffels et al., 2014). In agreement with this
prior work, we found that mCherry-TNPO1 is also present within
motile granules in axon terminals (Video S3).
Given that TNPO1 is expressed in axon terminals, and may
function as a molecular chaperone, we next investigated
whether modest overexpression of TNPO1 might restore FUS
RNP granule function in axon terminals treated with AdOx or ex-
pressing ‘‘cation-p enhanced’’ FUS constructs. As predicted,
mCherry-TNPO1 fully rescued new protein synthesis in both
AdOx-treated neurons and in neurons expressing ‘‘cation-p
enhanced’’ constructs (Figures 7E and 7I, p < 0.001). However,
mCherry-TNPO1 had no effect on new protein synthesis in
mock-treated (ADMA FUS) axon terminals.owing AdOx treatment of the axon terminals in (A). Phase state was assessed
ls, *p < 0.05, **p < 0.01.
creases FUS granules in live distal axon segments. Unpaired t test, n = 20–30
ock or AdOx treatment, or expressing FUS with additional arginines, and co-
ts, ns, not significant, *p < 0.05, ***p < 0.001. Error bars, SEM. Video S3 displays
ing ADMA FUS.
ons. Scale bar, 5 mm.
labeled newly synthesized proteins in mock-treated (ADMA FUS, left), AdOx-
+21R, right). Scale bar, 5 mm.
nt. **p < 0.01, ***p < 0.001. Error bars, SEM.
ted neurons and neurons expressing FUS with additional arginines. Unpaired
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DISCUSSION
The experimental data described here reveal that the phase
behavior of FUS is modulated by (1) the post-translational
methylation state of arginines in the structured C-terminal
domain and (2) by molecular chaperones such as TNPO1. This
conclusion provokes several broad lines of thought.
Cation-p Interactions and Cooperativity between N- and
C-Terminal Domains
Previous reports have shown that the N-terminal LC domain of
FUS (residues 1–214) is necessary and sufficient for phase sepa-
ration and gelation of FUS, anddoes so by forming intermolecular
b-sheet-rich fibrils. The experiments described here support and
extend this view. Thus, our AFM-IR experiments clearly reveal
that intermolecular hydrogen bonding between b sheet regions
contributes to both liquid droplet and hydrogel formation.
However, our data also lead to the conclusion that FUS phase
separation is regulated by additional factors beyond just the
intermolecular b-sheet-forming LC domain. The experiments
described here reveal that phase separation is also driven by
multivalent cation-p interactions, which occur physiologically
between multiple arginines in the sCTD and multiple tyrosines
in the LC domain. In support of this, we have shown that
cation-p pairing and FUS phase separation are impeded by
(1) replacement of C-terminal domain arginines by alanines,
(2) conversion of these arginines to citrullines, or (3) replacement
of N-terminal tyrosines with alanines. Conversely, we have
shown that phase separation is maintained by amino acid
replacements that preserve the cation-aromatic ring pairing
(i.e., arginine to lysine; tyrosine to phenylalanine), rather than
planar-p or planar-planar interactions. Finally, we have shown
that phase separation is augmented in an arginine dose-
dependent manner by increasing the number of arginines in the
C-terminal domain, presumably by enhancing the number of
cation-p interactions. Two further observations underscore the
importance of domains outside the LC domain in promoting
liquid phase separation and gelation of FUS. First, as shown
here, FUS phase separation is also modulated by TNPO1, which
binds to FUS via its structuredC-terminal domain. Second, fALS-
FUS mutations map predominantly to the C-terminal domain.
Additional work will be required to fully understand the me-
chanics of the co-operative interaction between the C-terminal
domain and the intermolecular b-sheet-forming LC domain.
Our mixing experiments suggest a model in which multivalent
cation-p interactions initiate phase separation, thereby bringing
LC domains close together in restricted volumes and at higher
local concentration. We propose that this close apposition per-
mits the formation of more stable, intermolecular hydrogen-
bonded b-sheet-rich condensates driven by the LC domain.
The transient nature of the condensation events that occur
when physically separate LC domain and C-terminal domain
proteins are mixed could arise through several mechanisms.
For instance, the untethered C-terminal proteins might be less
efficient in restraining the egress of LC domain peptides from
nascent condensates during initial sol/droplet phase separa-
tion. Alternatively, the untethered arginine-rich C-terminal
domain proteinsmight bind to tyrosines within the intermolecular732 Cell 173, 720–734, April 19, 2018b-sheet-forming parts of the LC domain, and interfere with
further condensation.
Converting Liquid Droplets to Gels
Our observation that some HYPO FUS assemblies contain re-
gions that are liquid droplet-like while other regions are gel-
like, suggests liquid droplet and hydrogel states are alternate
but mechanistically related, and potentially inter-convertible
states within a single FUS assembly. This interpretation is sup-
ported by theoretical work indicating that in systems close to a
critical point, variations in interaction strength or solvation vol-
ume can allow coexistence of phase separation and gelation
(Harmon et al., 2017).
TNPO1 as a Chaperone in Non-nuclear Compartments
There are likely to be active processes tomaintain FUS and other
phase-separating proteins in a dispersed state, and to reverse
gelled forms. As is the case for TDP43 (Go¨tzl et al., 2016), auto-
phagy and proteasome pathways are likely important compo-
nents of this quality control system. However, molecular chaper-
ones are also likely to be involved. Indeed, our experiments show
that TNPO1 is a molecular chaperone for ADMA FUS and HYPO
FUS that acts in distal axonal compartments of neurons, as well
as at the nuclear pore.
Methylation as a Physiological and Pathological
Regulator
Our observations that arginine methylation status profoundly
influences FUS phase separation, and that adding very small
amounts of unmethylated FUS (%5%) to ADMA FUS results in
rapid phase separation and gelation raises the possibility that
arginine methylation state might be a physiological method to
regulate FUS phase behavior. This conclusion raises several
critical questions. Which differentially methylated arginines are
essential for a change in FUS phase behavior? How do unmethy-
lated arginines increase the cation-p interaction strength? Are
specific tyrosines more important than others? In some Tudor
domain proteins, protein:protein binding occurs because of inter-
actions between asymmetrically dimethylated arginines on one
protein and specific clusters of aromatic amino acids on the other
protein that are arranged into three-dimensional ‘‘aromatic ca-
ges’’ (Tripsianes et al., 2011; Zhang et al., 2017). Does a similar
process occur during formation of the cation-p interactions in
FUS? If so, do unmethylated arginines alter the thermodynamics
of interactions with such ‘‘cages’’? Or do these unmethylated ar-
ginines simply form promiscuous interactions with tyrosines that
are not in specific clusters or cages, as proposed for other Tudor
domain proteins (Zhang et al., 2017)? Further work will be
required to address these questions. However, because the tyro-
sine-rich LC domain of FUS is natively disordered, if they exist,
such tyrosine clusters or cages are unlikely to have the same
highly ordered three dimensional structure of the tyrosine-based
‘‘aromatic cages’’ in Tudor domain proteins.
Finally, how is methylation and demethylation of individual
arginines regulated, both physiologically and pathologically?
Multiple PRMT enzymes are known, at least some of which
are components of RNP granules (Scaramuzzino et al., 2013).
However, to date, only a single arginine demethylase has been
identified (Jumonji domain-containing 6-JMJD6) (Blanc and Ri-
chard, 2017).
FUS and FTLD
While not directed at generating a model of FTLD-FUS, the ex-
periments reported here have obvious implications for under-
standing this disorder. Our observation that HYPO FUS and
fALS mutant FUS assemblies have similar biochemical and bio-
physical properties, and similar effects on FUS RNP granule
function, suggests that gel-like assemblies of hypomethylated
wild-type FUS and of fALSmutant FUS represent a common final
mechanism for FUS-related neurodegeneration.
We speculate that neuron subtype-specific differences in mo-
lecular chaperones, methylases, and demethylases might ac-
count for why hypomethylated non-mutant FUS accumulates
in fronto-temporal neurons in FTLD-FUS, while normally methyl-
ated fALS- mutant FUS accumulates in corticospinal and spinal
neurons in fALS-FUS. Why FUS becomes hypomethylated and
inadequately chaperoned in FTLD-FUS is unknown. Mutations
have not been detected in the PRMT genes tested to date. How-
ever, our results offer other candidate genes that are worth
investigating for disease-causing mutations, including TNPO1,
PADs, and JMJD6.
One important difference between our model and FTLD con-
cerns the fact that nuclear assemblies of FUS in FTLD contain
EWS, TAF15, and TNPO1. In our model TNPO1 is largely absent
from FUS aggregates. The explanation for this difference is not
immediately apparent. It might arise from the fact that in our
model the level of TNPO1 expression is not a limiting factor
because it is overexpressed. In contrast, in neurons TNPO1
might be titrated out by an excess of hypomethylated FUS.
Regardless, the work reported here provides a starting point to
investigate how pathological methylation and how pathological
phase separation of FUS that escapes from its normal molecular
chaperones might be targeted therapeutically.
Clearly, several reagents and methods developed here
including pFTAA, AFM-IR, and the cation-p-enhanced con-
structs will be useful tools to delve further into the biophysics
of FUS phase separation, and to create molecular models of
increased FUS phase separation propensity in FTLD-FUS.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Anti-FUS Santa Cruz Biotechnology, Heidelberg, Germany sc47711 RRID:AB_2105208
Anti-dimethyl-arginine asymmetric Merck Millipore, Watford, UK ASYM24 RRID:AB_310596
Anti-GAPDH Cell Signaling Technology, Danvers, USA 5174S RRID:AB_10622025
Anti-Puromycin-AlexaFluor647 Merck Millipore, Watford, UK MABE343-AF647
Rabbit polyclonal anti-mCherry Abcam Cat# ab167453; RRID:AB_2571870
Anti-Modified Citrulline Antibody, clone C4 EMD Millipore MABS487
Anti-FUS (Xenopus) Abcam ab70381
Bacterial and Virus Strains
E. coli BL21(DE3) New England Biolabs C25271
Chemicals, Peptides, and Recombinant Proteins
Thioflavin T Sigma 2390-54-7
pFTAA This manuscript N/A
Puromycin Sigma P8833
AdOx (Adenosine-20,30-dialdehyde) Sigma N/A
Bovine chymotrypsin Promega, Fitchburg, WI, USA N/A
AcTEV Protease ThermoFisher Scientific 12575015
ULP protease Purified in the lab N?A
PAD Cocktail, Active SignalChem P312-37C
Critical Commercial Assays
mMessage mMachine SP6 Transcription Kit ThermoFisher Scientific AM1340
polyadenylated using Poly(A)-tailing kit ThermoFisher Scientific AM1350
Deposited Data
Raw image data Mendeley Data https://doi.org/10.17632/4mjh8y579j.1
Experimental Models: Cell Lines
Human: SH-SY5Y neuroblastoma cells ATCC CRL-2266
Sf9 cells ThermoFisher Scientific N/A
DH10EMBacY Geneva Biotech N/A
Experimental Models: Organisms/Strains
Xenopus laevis Nasco LM00715MX
Recombinant DNA
pACEBac2 vector Geneva Biotech N/A
pOPINS vector This lab N/A
mCherry-TAF Table S1 N/A
mCherry-EWS Table S1 N/A
mCherry-Transportin-1 Table S1 N/A
FUS Table S1 N/A
FUS 6R/K Table S1 N/A
FUS 6R/A Table S1 N/A
FUS +16R Table S1 N/A
FUS +16R ncY/A Table S1 N/A
FUS +21R Table S1 N/A
FUS ncY/F Table S1 N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
FUS ncY/A Table S1 N/A
LC Table S1 N/A
CTD Table S1 N/A
Software and Algorithms
Proteome Discoverer version 2.1.0.81 software Thermo Scientific N/A
PEAKS Studio version 8 Bioinformatics Solutions Incorporated,
Waterloo, ON, Canada
N/A
ImageJ 1.50i (Java 1.8.0_131 (32-bit)) Wayne Rasband, NIH, USA https://imagej.nih.gov/ij/
Zen 2.3 SP1 Black (v14.0.0.201) Carl Zeiss Microscopy Gmbh RRID:SCR_013672
MATLAB Mathworks N/A
Volocity PerkinElmer N/A
GraphPad Prism GraphPad Software, Inc N/A
Other
m-slides glass bottomed chambers Ibidi GmbH, Germany N/A
ZnSe windows Platypus Technologies, USA N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter St
George-Hyslop (phs22@cam.ac.uk and p.hyslop@utoronto.ca).
EXPERIMENTAL MODEL DETAILS
Cell lines
SHSY-5Y cells were cultured in DMEMhigh glucosemedium (Sigma) supplemented with 10%FCS and 100 units/mL of penicillin and
100 mg/mL of streptomycin in a humidified incubator at 37C and 5%CO2. SH-SY5Y cells stably expressing EYFP-FUS were gener-
ated by electroporation, followed by selection with geneticin. Cells were transiently transfected with plasmids of EYFP-FUS, FUS
mutants, mCherry, mCherry-TAF, mCherry-EWS, and mCherry-TNPO1 using lipofectamine 3000 (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. AdOx (Adenosine-20,30-dialdehyde, Sigma), or equal volume of DMSO vehicle, was added to
cells for 24 hours at a final concentration of 20mM, unless otherwise stated in the figure legends.
Xenopus embryonic retina culture
Xenopus laevis embryos were fertilized in vitro and raised in 0.1x Modified Barth’s Saline at 18C. Capped mRNAs of mCherry,
mCherry-TNPO1 or FUS-GFP were synthesized using mMessage mMachine SP6 Transcription Kit (ThermoFisher Scientific), poly-
adenylated using Poly(A)-tailing kit (ThermoFisher Scientific), and injected into the two dorsal blastomeres at four-cell stage as
described (Leung and Holt, 2008). Eye primordia from stage 34 embryos were dissected and cultured in 60% L15 on laminin-coated
coverslips at 20C for 24 hours. This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment
Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB).
METHOD DETAILS
Expression and purification of FUS TNPO1, EWS and TAF15
Constructs encoding FUS residues 1-526 and its mutants, LC-mEmerald (aa1-214) and CTF-mCherry (aa215-526), were cloned into
pACEBac2 vector with a TEV cleavable N-terminal MBP tag and an EmGFP or mCherry-6xHis- C-terminal tag. Proteins were ex-
pressed and purified from insect Sf9 cells infected with the baculovirus. After four days of infection cells were harvested by spinning
at 4000rpm for 30minutes. Cell pellets weremixed with the resuspension buffer containing 50mMTris, 1M KCl, 0.1%CHAPS, 1mM
DTT, 5% glycerol at pH 7.4, and proteins purified using three steps purification scheme including, Ni-NTA affinity column, Amylose
affinity column followed by size exclusion chromatography in the buffer containing 50 mM Tris, 1 M KCl, 1 mM DTT, 5% glycerol at
pH 7.4. For Thioflavin T binding experiment, FUS samples were produced without the C-terminal GFP tag.
Constructs encoding full length human EWS or human TAF15 were cloned into pBACEBac2 vector with a TEV protease cleavable
N-terminal MBP tag. Proteins were expressed in Sf9 cells and purified on an amylose column. Fusion proteins were subjected to TEV
protease cleavage and the MBP tag was further removed by size exclusion chromatography.e2 Cell 173, 720–734.e1–e6, April 19, 2018
Gene encoding TNPO1 protein was cloned into pOPINS vector containing an N-terminal His-Sumo Tag and a ULP protease cleav-
age site separating the tag from TNPO1. Protein was expressed in E. coli BL21(DE3) in an overnight TB autoinduction media at 37C
for 5 hours followed by an overnight incubation at 25C. Cells were harvested and subjected to lysis using high pressure cell disrup-
tion system. Clarified lysate was loaded on a Ni-NTA column and purified using standard procedure. Protein containing fractions
were pooled, and dialysed in 25mM HEPES pH 7.5, 50mM NaCl, 1mM DTT and 5% glycerol buffer after addition of ULP protease
to remove the His-Sumo Tag. Protein was further purified on a size-exclusion column and the fractions containing purified protein
were pooled for all subsequent experiments.
For seeding experiments, a construct encoding full length FUS protein was cloned into pOPINS vector with an N-terminal His6-
SUMO tag. Protein was expressed in E. coli BL21(DE3) using TB autoinduction medium, with induction at 25C for 24 hours. Cells
were lysed by sonication and proteins purified on Ni-NTA resin, followed by buffer exchange step into 50 mM Tris, 500 mM NaCl,
pH 7.4.
Protein modification of FUS
For the preparation of hypomethylated FUS samples, the insect cell cultures were subjected to a repeated dose of 25mMAdOx solu-
bilised in DMSO for four days. Protein was subjected to same methods of purification as unmodified FUS.
For the preparation of citrullinated FUS sample, 20mg of Protein arginine deiminases (PAD) cocktail comprising five (PAD1-5) full
lengthGST tagged recombinant proteins wasmixedwith prewashed 50ml of anti-GST agarose bead in PAD cocktail buffer (0.1M Tris,
10mM CaCl2, pH 7.4). After incubating at 4
C for 1 hour, the sample was spun, supernatant was discarded and the beads were
washed three times with PAD buffer before being incubated with 100mg of purified Em-GFP- FUS protein in 100ml of PAD buffer
plus 200mM NaCl. The mixture was incubated at 37C shaking for 2 hours. Post incubation the sample was centrifuged and the
supernatant containing the citrullinated protein was collected and kept at 4C until further analysis.
Immunoprecipitation
AdOx treated YFP-FUS expressing SHSY-5Y cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% sodium
deoxycholate, 1% NP-40, 1 mM EDTA) with Protease and Phosphatase Inhibitor cocktail (Pierce) and 1mM PMSF for 20 minutes on
ice. Supernatants were cleared by centrifugation and equal amounts of protein taken for total lysate input or for immunoprecipitation
(IP) with anti-FUS antibody or normal mouse IgG control, followed by incubation with Protein G-Agarose (GE Healthcare) or
Dynabeads Protein G (Invitrogen). Beads were washed four times with RIPA buffer before the addition of 1x LDS sample buffer
(Thermo) containing 2.5 mM DTT (LSD/DTT), and samples analyzed by standard immunoblotting techniques. Protein expression
was quantified using densitometry analysis with ImageJ software, and the amount of ADMA-FUS, normalized to FUS input, was
expressed relative to control treated protein levels.
RIPA Insoluble FUS
Equal numbers of AdOx or DMSO treated YFP-FUS expressing cells were lysed directly in 1x LDS/DTT for input control, or in RIPA
buffer as performed for IP. Lysates were cleared of insoluble material by centrifugation (16,000 xg) at 4C, the RIPA soluble
supernatant diluted in 1x LDS/DTT, and the RIPA insoluble pellet washed again in RIPA buffer, re-centrifuged and suspended in
1x LDS/DTT. All samples were denatured by heated at 95C, and analyzed by immunoblotting.
FUS Droplet Assay
FUS purified proteins (0.5 mM-2 mM) were subjected to a series of NaCl concentration (40mM-500mM) in a total volume of 20 mL.
Samples were deposited on 8-well glass bottom Ibidi slides, incubated at room temperature for 10 minutes before being imaged
on a Zeiss Axiovert 200M microscope with Improvision Openlab software using 100X magnification objective. Droplet formation
was followed over time by collecting a series of images in both the bright field and FITC channels. ImageJ software was used in
all image processing. For all purified proteins nR 3.
LC-mEmerald and CTF-mCherry co-operative mixing experiments
Purified LC-mEmerald and CTF-mCherry were buffer exchanged to a buffer containing 150mMNaCl. 1mM each were mixed and the
concentration of the NaCl dropped to 50mM to induce droplet formation.
Turbidity Assay
2mM FUS protein was mixed with various NaCl concentrations in a 50 mL total volume in a Greiner 96 well half-are clear microplate.
Sample were incubated at room temperature for 10 minutes prior to the absorption (turbidity) measurement at 600nm in a
SpectraMax microplate reader. Readings were recorded in triplicate for each protein sample. All assays were performed in triplicate
(n = 3).
Thioflavin Binding
Thioflavin (ThT) binding was evaluated by monitoring ThT fluorescence. The ThT solution, containing 10mM of ThT in 50mM Tris,
40mM NaCl (pH 7.4) buffer, was mixed with 2mM of control treated FUS, 2mM AdOx treated FUS and 5mM Synuclein and incubatedCell 173, 720–734.e1–e6, April 19, 2018 e3
for 15 minutes at room temperature. Fluorescence emission spectra of ThT, excited at 446 nm, were recorded between 455 and
550 nm on a PerkinElmer LS55 luminescence spectrometer using excitation and emission bandwidths of 2.5 nm. All binding exper-
iments were carried out in triplicate (n = 3).
Circular dichroism
Circular dichroism (CD) spectrum of ADMA FUS, HYPO FUS, FUS +9R, FUS +16R, FUS +21R, FUS ncY/A, FUS ncY/F were
measured on a JASCO-810 Spectropolarimeter at 25C. 5mM of each purified protein was placed in a 1 mm path length quartz
cuvette and the far-UV spectrum recorded in the wavelength range of 195 – 250 nm. Scans were repeated ten times and then
averaged to yield a final spectrum for each construct.
pFTAA binding
Cells expressing FUS were imaged on m-slides glass bottomed chambers (ibidi GmbH, Germany). Pentameric formyl thiophene
acetic acid (pFTAA) was used at a concentration of 300nM diluted in PBS for cellular assays.
To image FUS in solution, borosilicate glass coverslips (VWR international, 223 22 mm, product number 631-0124) were cleaned
using an argon plasma cleaner (PDC-002, Harrick Plasma) for at least 1 h to remove any fluorescent residues. Prior to use, each batch
of cover-slides were tested for fluorescent artifacts. FUS was diluted at a concentration of 1 mM in low salt buffer, adding pFTAA at a
final concentration of 300nM. A drop of 8 mL of this mixture was placed over a coverslip and another coverslip was placed on top.
Imaging was performed using a 60x Plan Apo TIRF, NA 1.45 oil objective, (Nikon Corporation) mounted on an Eclipse TE2000-U
microscope (Nikon Corporation) fitted with a Perfect Focus unit. Fluorescence was collected by the same objective was separated
from the returning beam by a dichroic (Di01-405/488/532/635, Semrock), and passed through an emission filter (FF03-525/50-25,
Semrock) for both CFP and pFTAA signals. Cells expressing CFP-FUS were excited with a 405nm laser (LBX-405-50-CIR-PP,
Oxxius), while pFTAA was excited with a 488 nm laser (0488-06-01-0060-100, Cobolt MLD). The excitation power was 25 W/cm2
for both lasers measured in epifluorescence mode. Cells were imaged in epifluorescence mode, while protein in solution was imaged
in HiLo. The images were recorded on an EMCCD camera (Evolve 512, Photometrics) operating in frame transfer mode (EMGain of
6.8 e/ADU and 250 ADU/photon). Each pixel was 241 nm in length. The microscope was controlled with Micromanager software,
and bursts of images were recorded at 20 frames per second. Each analyzed image corresponds to an average of 50 images.
In the experiments mixing FUSwith TNPO1, the untagged FUS assemblies weremixed with an equimolar concentration of TNPO1,
and the same NaCl and pFTAA concentrations and imaging paradigms. The pFTAA-positive assemblies were automatically counted
using an ImageJ (NIH) macro with the function Find Maxima, and statistics were computed with MATLAB (Mathworks) and
GraphPad Prism.
Mass spectrometry and relative quantitation of FUS methylation
Samples of purified Sf9-cell expressed MBP-FUS-mEmerald from AdOx-treated and untreated cultures, totalling 100 mg of protein
each, were separately incubated at 60C for 30 minutes with 20 mM Tris(2-carboxyethyl)phosphine. Subsequently, sample solutions
were adjusted to 7.45 M urea and 45 mM 4-vinylpridine before being incubated in the dark for one hour. The denatured and reduced
protein samples were concentrated by centrifugation withinMicrocon YM-30 filter cartridges (EMDMillipore, Billerica, MA, USA). The
filters embedded in these cartridges were washed with 300ml of 10 mM triethylammonium bicarbonate (TEAB) then covered in 50 mL
of 10 mM TEAB containing 2 mg of bovine chymotrypsin (for methylation analysis) or porcine trypsin (for citrullination analysis)
(Promega, Fitchburg, WI, USA) and shaken for five minutes at 600 rpm.Proteolytic digestion was carried out at 37C for 14 hours.
Next, peptides were collected by passing the digest and an additional 50 ml volume of 0.5 M NaCl through the cartridges. Chymo-
tryptic digests were divided for unlabeled and iTRAQ analyses. One aliquot of each digest was diluted with 20 ml of 1 M TEAB before
addition of iTRAQ 8plex reagent in 210 mL of ethanol (Sciex, Concord, ON, Canada). iTRAQ reaction mixtures were left for 2 hours
then concentrated in a centrifugal evaporator at 36C before being diluted in 100 mL of 0.1% formic acid in water then combined.
The samples were acidified with formic acid then desalted using Bond Elut OMIX C18 pipette tips (Agilent, Santa Clara, California
USA) according to the manufacturer’s instructions. Desalted samples were concentrated in a centrifugal evaporator at 36C, diluted
in 0.1% formic acid, and analyzed on an Easy-nLC 1000-Orbitrap Fusion system (Thermo Scientific, Waltham, MA, USA). Mass
spectra were collected over 60-minute-long HPLC runs, during which the acetonitrile content of the mobile phase was increased
from 0 to 30% (v/v) over 40 minutes, then to 99.9% over 10 minutes and finally held at 99.9% acetonitrile for 10 minutes. The two
mobile phases used were water and acetonitrile, each with 0.1% formic acid (v/v). The flow rate of the HPLC system was 300 nl/
min and the Acclaim PepMap RSLC (Thermo Scientific) analytical column used was 25 cm long with a 75 mm internal diameter,
packed with 2 mm C18 particles having 100 A˚ pores.
All mass spectra were collected in positive ion mode with a nanoflow electrospray ionization source potential of 2200 V and an ion
transfer tube temperature of 275C. The data acquisition cycle for the iTRAQ analysis was 3 s long, beginning with an orbitrap
precursor ion scan fromm/z 400 to 2,000 at a resolution of 30,000 followed by MS2 scans and MS3 scans of the most abundant pre-
cursor ions and their dissociation products respectively. The MS3 spectra were collected at a resolution of 30,000. Ions detected
in any survey scan having charge states less than 2 or greater than 6 or having intensities under 10,000 counts or that had been
subjected to MS2 four times in the preceding 20 s of analysis were excluded from MS2 and MS3. Instrument parameters used in
the analysis of unlabelled samples were identical to those used in the iTRAQ analysis, except MS3 scans were omitted.e4 Cell 173, 720–734.e1–e6, April 19, 2018
Peptide sequencing and quantification from the LC-MS data were performed on Proteome Discoverer version 2.1.0.81 software
(Thermo Scientific) with peptide-to-spectrum matches produced by Sequest HT. Cleavage specificity was set to the C-termini of
phenylalanine, leucine, tryptophan and tyrosine residues with up to two missed cleavages allowed. Precursor and product ion
mass tolerance were 20 ppm and 0.4 Da respectively. The FASTA protein database used for the search included all human canonical
and isoform entries (Uniprot version Dec 20, 2015, downloaded Mar 1, 2016), all Uniprot annotated Spodoptera frugiperda entries
(downloaded Mar 13, 2017), bovine chymotrypsin (Uniprot accessions P00766, P00767, Q7M3E1), the small ubiquitin-like modifier
of Saccharomyces cerevisiae (Uniprot accession Q12306), as well as the sequence of the MBP-FUS-mEmerald construct. False
discovery rate estimation was performed using Percolator and quantification was undertaken with Reporter Ion Quantifier algorithm,
both under default settings. The mass spectra were also interpreted using PEAKS Studio version 8 (Bioinformatics Solutions
Incorporated, Waterloo, ON, Canada) with default settings.
AFM-IR
Analysis by conventional Atomic Force Microscopy and nanoIR2 (Anasys Instrument, USA) was performed on hydrophobic ZnSe
windows (Platypus Technologies, USA). An aliquot of 10 ml of each sample was deposited on the surface for 1 minute. Successively,
the droplet was rinsed by 1 mL of Milli-Q water and dried by a gentle stream of nitrogen.
A nanoIR2 platform (Anasys, USA), which combines high resolution and low noise AFM with a tunable OPO laser with top
illumination configuration was used. The samples morphology was scanned by the nanoIRmicroscopy system, with a rate line within
0.05-0.2 Hz and in contact mode. A silicon gold coated PR-EX-nIR2 (Anasys, USA) cantilever with a nominal radius of 30 nm and an
elastic constant of about 0.2 N/mwas used. In order to avoid and reduce polarization effects, because of the gold coating of the tip, IR
light was polarized parallel to the surface of deposition. All images were acquired with a resolution between 800x200 and 1000x500
pixels per line. The AFM images were treated and analyzed using SPIP software. The height imageswere first order flattened, while IR
and stiffness related maps where only flattened by a zero order algorithm (offset). Average frequency shift, related to the intrinsic
stiffness of the sample (Volpatti et al., 2016), was calculated on 3 WT, 4 hypo-methylated (HM) and 4 FUS +16R droplets. The last
ones could be divided into different regions according to their relative stiffness. Relative stiffness was calculated as the normalized
ratio of the average frequency shift of each region. The relative values were measured at both the 1st and 2nd resonance of oscillation
of the cantilever with consistent results.
The spectra were collected by placing the AFM tip on the top of the FUS droplets (Figure S1) with a laser wavelength sampling of
2 cm-1 with a spectral resolution of 4 cm-1 and 256 co-averages, within the range 1400-1800 cm-1 (Mu¨ller et al., 2014).
Within a droplet, several spectra at different positions were acquired. For each droplet, an average spectrum was obtained as the
average of the spectra at different positions within its area and by subtracting the baseline signal of the substrate. Successively, they
were smoothed by Savitzky-Golay filter (second order, 9 points) and normalized. Spectra second derivatives were calculated and
smoothed by Savitzky-Golay filter (second order, 9 points)). In total, 55 spectra were acquired for three methylated FUS droplets,
73 spectra for four hypo-methylated assemblies and 88 for four FUS +16R droplets. Relative secondary and quaternary organization
was evaluating integrating the area of the different secondary structural contribution in the amide band I. Spectra were analyzed using
the microscope’s built-in Analysis Studio (Anasys) and OriginPRO. All measurements were performed at room temperature and with
laser power between 1%–4% of the maximal one and under controlled Nitrogen atmosphere with residual real humidity below 5%.
Quantification of cells with FUS granule clusters
For live cells, images were taken immediately after 24 h mock and AdOx treatment. For fixed cell quantification, cells were initially
fixed with 4% PFA in medium at 37C for 15 min and then with 4% PFA in PBS at room temperature for 15 min. Hoechst or DAPI
was used for nuclear counter-staining. Images were taken using a Zeiss 710 confocal microscope. For transient transfected cells,
AdOx was added 3 hours before transfection. All the experiments were replicated at least three times. To quantify the percentage
of cells with FUS granule clusters, more than 250 cells were counted for each sample.
Immunocytochemistry, puromycin labeling and imaging in retinal cultures
For immunocytochemistry detecting endogenous FUS proteins, heat-induced antigen retrieval in sodium citrate buffer (10mM
sodium citrate, 0.05% Tween 20, pH 6.0) was performed after 4% paraformaldehyde/15% sucrose fixation. Cultures were
subsequently permeabilized with 0.1% Triton (Sigma) for 5 minutes, blocked in 5% heat-inactivated goat serum and incubated at
4C overnight with anti-FUS antibody (Abcam, ab70381). For puromycin labeling, axons pre-treated with DMSO or 20mM AdOx
for 30minutes were severed from their cell bodies and subsequently incubated with 10mg/ml puromycin (Sigma) for 10minutes. After
fixation, permeablisation and blocking steps, puromycin-incorporated nascent peptides were labeled with Alexa Fluor 647-
conjugated anti-puromycin antibody (1:250, Millipore) overnight. 161 Randomly selected noncollapsed growth cones in each
condition from 3 independent biological replicates were imaged using a Nikon Optiphot inverted microscope equipped with a 60x
oil-immersion objective and a CCD camera (Hamamatsu).
For quantitation of fluorescence intensity, the growth cone outline was traced on the phase contrast image using Volocity
(PerkinElmer), then superimposed on the fluorescent image. The software calculated the fluorescent intensity within the growth
cone, giving a measurement of pixel intensity per unit area. The growth cone outline was then placed in an adjacent area clear of
cellular material to record the background fluorescent intensity. This reading was subtracted from the growth cone reading, yieldingCell 173, 720–734.e1–e6, April 19, 2018 e5
the background-corrected intensity. All quantitative analysis was performed ‘blind’ to experimental condition and normalized to the
control.
FUS-GFP fluorescence in live distal axon segments was imaged under a Perkin Elmer Spinning Disk UltraVIEWERS, Olympus IX81
invertedmicroscope with a 60x 1.4NA silicone oil objective, equippedwith a Flash4.0 camera (Hamamatsu). Imageswere acquired at
maximum speed for 1 minute with 500ms exposure time.
QUANTIFICATION AND STATISTICAL ANALYSES
In all figures the mean and SEM are described along with the number of biological replications, and the statistical tests applied.
DATA AND SOFTWARE AVAILABILITY
Raw image data of full western blots are deposited in Mendeley Data at https://doi.org/10.17632/4mjh8y579j.1.e6 Cell 173, 720–734.e1–e6, April 19, 2018
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Figure S1. 25 mM AdOx Treatment Significantly Reduces Asymmetric Dimethylation of FUS Purified from Sf9 Cells, Related to Figure 1
(A) Left: Representative western blot of MBP-FUS-EmGFP protein purified from Sf9 cells after 4 days of 25mM AdOx, or DMSO control. Right: Quantification of
western blots. n = 4 per experimental group, one-tailed, Mann-Whitney U test, *p% 0.05, error bars = SEM.
(B) Top: FUS dimethylation sites differ in their apparent susceptibility to AdOx treatment. Depicted are the relative proportion of peptide-to-spectrum matches
(CID MS2 spectra of unlabeled peptides identified with the PEAKS algorithm) comprising a given FUS arginine residue observed in an unmodified, mono- or
dimethylated state. For most FUS arginine residues, methylation decreased in AdOx treated relative to mock treated cells, except for R394 and R481 which were
consistently observed to be dimethylated. Middle: Orbitrap CID MS2 spectrum of a chymotryptic FUS peptide dimethylated at R407 identified with confidence
exceeding 99%. The other arginine residue present (R422) was unmodified, as evidenced by a continuous y-ion series indicating no post-translational
modification in this part of the peptide. The spectrum is representative of 77 peptide-to-spectrum matches for this region of FUS, which consistently identified
(mono or di) methylated R407 accompanied by unmodified R422.Bottom left: Evidence for AdOx-dependent inhibition of argininemethylation. The graph depicts
(legend continued on next page)
the relative ratios of unmethylated, monomethylated and dimethylated versions of the FUS peptides 209-GQQDRGGRGRGGSGGGGGGGGGGY-232 and 398-
GGGGSGGGGRGGFPSGGGGGGGQQRAGDW-426 in untreated and AdOx-treated FUS preparations. Circles represent individual quantifications. The number
of quantifications (based on separate peptide-to-spectrum matches) underlying each cumulative quantification are listed above the graph. Horizontal marks
depict median Log2 ratios for a given peptide and modification. Bottom right: AdOx treatment did not affect overall abundance of peptides in untreated versus
AdOx-treated samples. Abundance ratios of nine chymotryptic peptides from the MBP-FUS-EmGFP. All peptides depicted either lack arginine residues or
contain arginine residues but were not observed to be methylated or dimethylated.
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Figure S2. Hypomethylated FUS and FUSwith Additional Arginines Have CDSpectra, Are Indistinguishable fromADMACitrullination of FUS,
and so Are Likely to Be Properly Folded; Protein Arginine Deiminase Treatment Converts Arginines to Citrulline, Related to Figure 2
(A) Circular dichroism (CD) spectrum of ADMA FUS, Hypo-FUS, 9R, 16R, 21R, ncY/A, ncY/F were measured on a JASCO-810 Spectropolarimeter at 25C.
5mMof each purified protein was placed in a 1 mm path length quartz cuvette and the far-UV spectrum recorded in the wavelength range of 195 – 250 nm. Scans
were repeated ten times and then averaged to yield a final spectrum for each construct.
(B) At 1mM FUS and 50 mM NaCl, FUS undergoes phase transition. Upon addition of active PAD (in presence of calcium) phase transition is abrogated.
(C) Representative western blots showing: top panel: anti-modified citrulline antibody detects a band in FUS + active PAD sample. Middle panel: equal FUS
protein loading is detects by anti-FUS antibody. Bottom panel: Coomassie staining also detects equal FUS protein loading in each sample.
(D) Orbitrap ETD MS2 spectrum of a tryptic FUS peptide citrullinated at R514 and R518 identified with confidence exceeding 99% from a PAD treated FUS
preparation.
DA
C
RIPA soluble FUS
GAPDH input
FUS input
RIPA insoluble FUS
80
80
80
40
Y
FP
Y
FP
-F
U
S
 6
R
→
K
Y
FP
-F
U
S
 6
R
→
A
Y
FP
-F
U
S
ADMA
FUS
HYPO
FUS
Y
FP
Y
FP
-F
U
S
 6
R
→
K
Y
FP
-F
U
S
 6
R
→
A
Y
FP
-F
U
S
80 RIPA insoluble FUS 
(long exp)
ADMA FUS
HYPO FUS
YF
P-
FU
S
YF
P-
FU
S 
6R
→A
YF
P-
FU
S 
6R
→K
YF
P-
FU
S
YF
P-
FU
S 
6R
→A
YF
P-
FU
S 6
R→
K
0.0
0.2
0.4
0.6
0.8
1.0
In
so
lu
bl
e 
YF
P
- F
U
S
le
ve
ls
 n
or
m
al
is
e d
 to
YF
P
-F
U
S
 in
pu
t (
A
U
)
YFP-FUS
YFP-FUS
6R→A
YFP-FUS
6R→K
A
D
M
A 
FU
S
H
Y
P
O
 F
U
S
YF
P
YF
P-
FU
S
YF
P-
FU
S 
6→
A
YF
P-
FU
S 
6→
K
YF
P
YF
P-
FU
S
YF
P-
FU
S 
6→
A
YF
P-
FU
S 
6→
K
0
20
40
60
80
100
*
***
C
el
ls
 w
ith
 F
U
S
 g
ra
n u
le
cl
us
te
rs
 ( %
)
ADMA FUS
HYPO FUS
***
***
***
B
80
80
40
80
α-ADMA
α-FUS
α-FUS
α-GAPDH
To
ta
l l
ys
at
e
FU
S
 IP
Ig
G
FU
S
 IP
AdOx
AD
MA
 Y
FP
-F
US
HY
PO
 Y
FP
-F
US
0
20
40
60
80
100
120 *
N
or
m
al
is
ed
 A
D
M
A
le
ve
ls
 (%
 c
on
tro
l) Y
FP
-F
U
S
 +
21
R
Y
FP
-F
U
S
 +
16
R
Y
FP
-F
U
S
 +
9R
Y
FP
-F
U
S
 +
7R
Y
FP
-F
U
S
 +
5R
A
D
M
A 
Y
FP
-F
U
S
H
Y
P
O
 Y
FP
-F
U
S
Y
FP
-F
U
S
 n
cY
→
A
80
80
80
40
80
RIPA soluble FUS
GAPDH input
FUS input
RIPA insoluble FUS
RIPA insoluble FUS 
(long exp)
Figure S3. Substitution of Alanine for Six Arginines that Are Differentially Methylated Reduces FUS Aggregation Propensity after AdOx
Treatment, whereas Lysine Substitution Still Supports FUS Aggregation Propensity, Related to Figure 3
(A) AdOx treatment causes hypomethylation of YFP-FUS in SH-SY5Y cells. Representative image of a western blot of immunoprecipitation of YFP-FUS from SH-
SY5Y cells showing a significant reduction in asymmetrically dimethylated arginine (ADMA) epitopes after AdOx treatment. Unpaired t test, n = 5, *p < 0.05, error
bars = SEM.
(legend continued on next page)
(B) Western blot analysis of RIPA soluble and insoluble FUS in SH-SY5Y cells expressing YFP-FUS with or without AdOx treatment (HYPO and ADMA FUS
respectively), or mutant FUS including FUSwith fewer tyrosine residues (ncY/A) or more arginine residues (quantified in Figure 3E). Cells were lysed directly into
loading buffer to determine FUS input. Hypomethylation of FUS results in increased levels of insoluble FUS with a concomitant decrease in soluble FUS, as does
increasing the number of arginine residues, in a dose-dependent manner. ADMA and ncY/A FUS are predominately soluble but a longer exposure shows that
FUS ncY/A is more soluble compared to ADMA FUS.
(C) Representative confocal images of SH-SY5Y cells expressing YFP-FUS with 6 arginine residues mutated to alanine (6R/A) or lysine (6R/K), with DMSO
(ADMA FUS) or AdOx treatment (HYPO FUS), with quantification of the number of cells with nuclear granule clusters on the right. Scale bar = 10 mm. Number of
cells counted > 100. One-way ANOVA with Tukey posthoc test, n = 3, *p < 0.05, ***p < 0.001, error = SEM.
(D) Mutating the same 6 arginine residues to alanine (6R/A), but not lysine (6R/K), leads to reduced levels of AdOx induced (HYPO FUS) RIPA insoluble FUS
compared to wild-type with quantification of the amounts of RIPA insoluble FUS on the right. One-way ANOVA with Tukey posthoc test, n = 4, ***p < 0.001,
error = SEM.
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Figure S4. TNPO1 Expression Does Not Affect FUS Expression and Does Not Change Asymmetric Methylation Caused by AdOx Treatment,
Related to Figure 4
(A) FUS immunoprecipitation and western blot studies show that overexpression of mCherry-TNPO1 has no effect on total YFP-FUS expression or FUS
methylation. Representative of n = 3.
(B) mCherry western blotting studies show that AdOx treatment has no effect on TNPO1, EWS, TAF15 or FUS expression. Representative of n = 3.
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Figure S5. pFTAA Binds and Fluoresces with HYPO FUS but Not ADMA FUS, whereas ThT Only Binds and Fluoresces Very Weakly to HYPO
FUS or ADMA FUS, Related to Figure 5
(A) Phase-separated FUS assemblies only weakly bind ThT. Fluorescence spectroscopy reveals weak ThT binding to methylated FUS (black line) but stronger
ThT binding to hypomethylated FUS (red line). No fluorescence was detected from methylated FUS (yellow line), hypomethylated FUS (blue line) or ThT alone
(green line). ThT binding to a-synuclein generated > 5-fold greater fluorescence (purple line).
(B) Phase-separated FUS assemblies bind pFTAA, especially hypomethylated FUS.
Plot of pFTAA fluorescent assemblies permm2 for either ADMA FUS or hypomethylated FUS with and without TNPO1. There is strong pFTAA fluorescence from
hypomethylated FUS assemblies which is dramatically reduced in the presence of equimolar amounts of TNPO1. Kruskal-Wallis with Dunn’s post hoc, n > 40
droplets over 3 replications, ***p < 0.001, NS = not significant, error bars = SEM.
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Figure S6. Nanoscale Infrared Spectroscopy Reveals that ADMA, HYPO FUS, and FUS+16R Assemblies Display Different Stiffness and
Secondary and Quaternary Organization, Related to Figure 6
(A) AFM tip-sample Contact Frequency measurements of ADMA and HYPO FUS assemblies. The average frequency shift for 3 different ADMA-FUS droplets
(green), for 6 regions within 4 different HYPO FUS droplets (red and orange) and 5 regions within 4 FUS +16R droplets, with the relative standard deviation.
(B) Average IR spectrum of each measured ADMA, HYPO and FUS +16R granules and their average.
(C and D) Second derivatives of IR spectra at specific wavenumbers of each individual ADMA, HYPO and FUS+16R granules and their average. We acquired a
total of 55, 73, 88 spectra for the WT, HYPO and +16R droplets, respectively. ADMA and +16R droplets show higher degrees of homogeneity than HYPO ones,
which show higher structural heterogeneity.
(E) The relative conformational change between ADMA and HYPO -FUS assemblies is displayed as histograms, and shows increased random coil, b-turn and
antiparallel b sheet content (black bars), and decreased native b sheet and a-helical content (white bars) in HYPO FUS assemblies.
(D) HYPO FUS assemblies show lower and shifted signals of methyl group absorption (das(CH3), methyl asymmetric stretching), confirming a lower methylation
state of HYPO FUS assemblies. Error bars = SEM.
